Hologic Announces Two New Respiratory Assays for the Detection of COVID-19, Flu A, Flu B and RSV
Hologic, Inc. (Nasdaq: HOLX) announced today that it is now offering its Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay and its Novodiag® RESP-4 molecular diagnostic test for sale in the European Union in time for the northern hemisphere’s respiratory viral season. Both assays detect and differentiate four of the most prevalent respiratory viruses that can present with similar clinical symptoms: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A (Flu A), influenza B (Flu B) and respiratory syncytial virus (RSV).
The Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is a high-performance cartridge-based assay that runs on the fully automated high-throughput Panther Fusion system. The test uses nasopharyngeal swab samples.
The Novodiag RESP-4 assay runs on the Novodiag system, the fully automated molecular diagnostic solution that delivers on-demand testing for infectious disease and antimicrobial resistance. This test also uses nasopharyngeal swab samples and includes an embedded cellularity control to ensure that the sample was correctly taken.
Both products are compliant with the European In Vitro Diagnostic Medical Device Directive (IVDD) 98/79/EC, and transition provisions for such devices included in the IVD Regulation (EU) 2017/746.
“As we move into the next phase of COVID, it is important that we evolve our assays to support our customers with tests that enable them to differentiate between the multiple respiratory pathogens as easily as possible. The ability to accurately differentiate between respiratory viruses with similar symptoms is essential if physicians are to ensure optimized care for each patient,” said Jan Verstreken, Group President International. “Together, these two assays further build our international offering of molecular diagnostic scalable solutions that meet the growing needs of a broad range of customers, from single-patient rapid testing to population-level screening.”
He continued, “The RESP-4 assay, developed and manufactured in Espoo, Finland is the first new Novodiag assay to be launched since Hologic’s acquisition of Mobidiag in June 2021. The Panther Fusion SARS-CoV-2/Flu A/B/RSV assay was developed and will be manufactured at our facility in San Diego, CA. It adds to our quickly growing menu of Panther Fusion assays, including the Panther Fusion EBV and BKV assays designed and manufactured at our recently acquired facility in Liège, Belgium.”
The launch of the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay adds to the respiratory portfolio for the Panther Fusion system, which currently includes the Panther Fusion Flu A/B/RSV assay, the Panther Fusion Paraflu (Parainfluenza 1/2/3/4) assay, the Panther Fusion AdV/hMPV/RV (adenovirus/human metapneumovirus/rhinovirus) and the Panther Fusion Bordetella assay.
The launch of the Novodiag RESP-4 assay further expands the Novodiag assay menu, which currently includes diagnostic assays for gastrointestinal infections, hospital acquired infections, antimicrobial resistance and respiratory infections.
For more information visit www.hologic.com.
About the Panther and Panther Fusion Systems
The Panther molecular diagnostics system is a best-in-class, fully automated, sample-to-result platform that can be used in low-, medium- or high-throughput laboratories. With a small footprint, adaptable workflow options and consolidated testing menu, it combines women’s health, sexually transmitted infection and viral load testing, which can all be done simultaneously. The Panther Fusion system provides an expanded in vitro diagnostics menu, as well as Open AccessTM functionality to run laboratory developed tests.
About the Novodiag System
The Novodiag system combines real-time PCR and microarray capabilities that enable multiple pathogens to be identified in a single sample, providing a simple and fast way to pinpoint patients most at risk with targeted and syndromic on-demand testing. It delivers clinically relevant results in central labs or tertiary settings and its rapid ‘sample-in, result-out’ system allows for the fully automated detection of novel coronavirus in approximately one hour. It can be used as the main molecular platform for emergency, decentralised, and out-of-hours testing, or in association with the Panther® System.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
Forward Looking Statements
This press release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic’s diagnostic products. There can be no assurance that these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient. The actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to publicly release any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
Hologic, The Science of Sure, Mobidiag, Novodiag, Panther, Panther Fusion and associated logos are trademarks and/or registered trademarks of Hologic, Inc. in the United States and/or other countries.
SOURCE: Hologic, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005201/en/
Contact information
Investor Contact:
Ryan Simon
+1 858.410.8514
ryan.simon@hologic.com
Media Contact:
Jane Mazur
+1 508.263.8764
jane.mazur@hologic.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Armis Recognized for Innovation; Named to Inc. Best in Business List for the Second Consecutive Year2.12.2025 14:00:00 EET | Press release
Armis, the cyber exposure management & security company, today announced that it has once again been named to Inc.’s Best in Business list, specifically highlighted in the Best in Innovation category for 2025. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made a profound impact on their industries and on society at large. “Armis rapidly innovates and continuously enhances our comprehensive Cyber Exposure Management Platform so that global organizations can proactively protect against cyber threats before there’s any impact,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “Unlike other solutions on the market, Armis addresses the entire lifecycle of managing cyber threats so that security teams no longer reactively respond to breaches. This is a strategic and monumental shift for the industry to stay a step ahead of threat actors and hugely beneficial to keeping society as we know it safe from disruptions.” Since
Egle Therapeutics Initiates Phase 1 Healthy Volunteer Study of EGL-003, a Next Generation Treg IL-2 Agonist for Atopic Dermatitis2.12.2025 13:32:00 EET | Press release
Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company developing precision medicines that modulate regulatory T cells (Tregs) to restore immune balance, today announced dosing of the first healthy volunteer in the Phase 1 clinical study of EGL-003, an IL‑2⍺-biased mutein designed to selectively activate Tregs while limiting effector T cell stimulation, as a potential treatment for atopic dermatitis. The open-label, multi-center Phase 1 trial begins with a single ascending dose portion in healthy volunteers to rapidly generate foundational safety, pharmacokinetic (PK), and pharmacodynamic (PD) data. These findings will inform dose selection and scheduling for the subsequent multiple ascending dose portion in approximately 40 adults with atopic dermatitis (AD), which will evaluate safety, PK/PD, and early clinical activity versus placebo. Data from both study segments are expected to guide dose selection for a planned Phase 2a trial in AD aimed at establishing clinical pro
AI Takes Center Stage as the Major Threat to Cybersecurity in 20262.12.2025 13:00:00 EET | Press release
Experian® today released its 2026 Data Breach Industry Forecast, offering a look at the evolving cyber threat landscape. The predictions address how the coming year could usher in a new wave of sophisticated attacks driven by artificial intelligence along with other threats and vulnerabilities including quantum computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202474758/en/ Experian's 2026 Data Breach Industry Forecast Now in its 13th year, the forecast offers six insights into how cybercriminals are leveraging emerging technologies to create more convincing identities, evade detection, and exploit new digital frontiers. From synthetic profiles and autonomous AI agents to shape-shifting malware and even brain-computer interface vulnerabilities, the 2026 predictions point to a future where cyberattacks are more personalized, persistent, and technologically advanced than ever before. To download the complimentary pa
Buro Happold Signs Landmark Agreement with Expo 2030 Riyadh Company to Deliver Detailed Master Plan and Infrastructure and Public Realm Design for Expo 2030 Riyadh2.12.2025 12:00:00 EET | Press release
Buro Happold, a leading global engineering, design and advisory consultancy, has signed a major contract with Expo 2030 Riyadh Company to serve as the lead design consultant for the detailed master plan and detailed design of public realm, landscape, infrastructure and utilities for Expo 2030 Riyadh and its legacy. This partnership represents a significant step toward delivering an event billed as “An Unprecedented World Expo”. Expo 2030 Riyadh is expected to feature nearly 197 participating countries and attract over 42 million visits to Pavilions covering approximately 6 million sqm. The event will offer a unique opportunity for participants to address shared challenges and showcase pioneering solutions for a sustainable future. Under the agreement, Buro Happold will provide comprehensive design and technical services, including, development of the detailed master plan, including a focus on event requirements and legacy phase elements, detailed design of the infrastructure works, uti
ThetaRay Report Warns Europe’s AML System at ‘Breaking Point’ as New Regulations Make AI Adoption Inevitable2.12.2025 12:00:00 EET | Press release
ThetaRay, a global leader in Cognitive AI financial crime compliance, today released a landmark study on the future of anti-money laundering in Europe. The study warns that Europe’s anti-money laundering (AML) system is approaching structural failure, and that financial institutions will be unable to meet upcoming supervisory expectations without advanced AI-driven monitoring and customer screening systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202058684/en/ Next Generation AML Solutions The report, “Next-Generation AML Solutions: An Analysis of AI-Based Tools vis-à-vis the Reform of the European AML Institutional and Substantive Architecture,” offers some of the most comprehensive examinations to date of how the EU’s sweeping AML reform package and the Artificial Intelligence Act will reshape compliance across the region. Co-authored by Prof. Andrea Minto, a leading authority on EU financial regulation at Ca’ Fo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom